Other

Cash Equivalents, Debt and Equity Securities, Cost

Vertex Pharmaceuticals Cash Equivalents, Debt and Equity Securities, Cost increased by 1.0% to $10.07B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 24.3%, from $8.10B to $10.07B. Over 2 years (FY 2023 to FY 2025), Cash Equivalents, Debt and Equity Securities, Cost shows relatively stable performance with a -2.0% CAGR.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ4 2023
Last reportedQ1 2026
Metric ID: other_cash_equivalents_debt_and_equity_securities_cost

Historical Data

10 periods
 Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$10.39B$11.30B$7.51B$8.12B$8.37B$8.10B$8.06B$8.26B$9.98B$10.07B
QoQ Change—+8.7%-33.6%+8.2%+3.0%-3.2%-0.5%+2.4%+20.8%+1.0%
YoY Change————-19.5%-28.3%+7.4%+1.7%+19.3%+24.3%
Range$7.51B – $11.30B
CAGR-1.4%
Avg YoY Growth+0.8%
Median YoY Growth+4.5%
Current Streak3 quarters growth

Frequently Asked Questions

What is Vertex Pharmaceuticals's cash equivalents, debt and equity securities, cost?
Vertex Pharmaceuticals (VRTX) reported cash equivalents, debt and equity securities, cost of $10.07B in Q1 2026.
How has Vertex Pharmaceuticals's cash equivalents, debt and equity securities, cost changed year-over-year?
Vertex Pharmaceuticals's cash equivalents, debt and equity securities, cost increased by 24.3% year-over-year, from $8.10B to $10.07B.
What is the long-term trend for Vertex Pharmaceuticals's cash equivalents, debt and equity securities, cost?
Over 2 years (2023 to 2025), Vertex Pharmaceuticals's cash equivalents, debt and equity securities, cost has grown at a -2.0% compound annual growth rate (CAGR), from $10.39B to $9.98B.